Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Nektar Therapeutics (NASDAQ: NKTR) closed at $0.69 in the last session, up 1.46% from day before closing price of $0.69. In other words, the price has increased by $1.46 from its previous closing price. On the day, 1.11 million shares were traded.
Ratios:
We take a closer look at NKTR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.24 and its Current Ratio is at 3.24. In the meantime, Its Debt-to-Equity ratio is 13.59 whereas as Long-Term Debt/Eq ratio is at 12.00.
On March 14, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $6.
On January 08, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.B. Riley Securities initiated its Buy rating on January 08, 2025, with a $4 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 19 ’25 when Zalevsky Jonathan bought 10,712 shares for $0.67 per share.
Wilson Mark Andrew bought 9,996 shares of NKTR for $6,710 on May 19 ’25. On May 19 ’25, another insider, ROBIN HOWARD W, who serves as the Officer of the company, bought 23,208 shares for $0.67 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.48 while its Price-to-Book (P/B) ratio in mrq is 9.41.
Stock Price History:
Over the past 52 weeks, NKTR has reached a high of $1.81, while it has fallen to a 52-week low of $0.43. The 50-Day Moving Average of the stock is -2.03%, while the 200-Day Moving Average is calculated to be -30.92%.
Shares Statistics:
A total of 186.10M shares are outstanding, with a floating share count of 179.37M. Insiders hold about 3.62% of the company’s shares, while institutions hold 65.56% stake in the company.
